United States: The On-Sale Bar For Patents Could Be Available For Private Sales Under AIA

Last week, in Helsinn Healthcare SA v. Teva Pharmaceuticals USA Inc., the Court of Appeals for the Federal Circuit ("CAFC") ruled that the America Invents Act's on-sale bar provision renders patents invalid if the invention was sold prior to patenting, even if the sale did not publicly disclose the invention.

The on-sale bar invalidates a patent if the claimed invention is sold more than a year prior to the filing of the patent application. Prior to the AIA, federal courts held that all sales, confidential and public, triggered the on-sale bar. The AIA, effective on patents filed after March 16, 2013, amended the on-sale bar to state that an individual is entitled to a patent unless the claimed invention was patented or "in public use, on sale or otherwise available to the public" more than a year before a patent is filed. The "otherwise available to public" phrase led many to believe, including Helsinn (the plaintiff-patentee), that only public sales which disclosed the invention to the public triggered the on-sale bar under the AIA. The Federal District Court of New Jersey echoed this understanding when it found that only public sales disclosing the invention activate the on-sale bar.

The CAFC disagreed, and overturned the district court's holding. Before the CAFC, Helsinn argued that the AIA amendments to the on-sale bar left only publicly disclosed sales (i.e., those that disclose the invention itself to the public) with the power to invalidate a patent. The Federal Circuit, in its first interpretation of the amended statute, stated that such a finding "would work a foundational change in the theory of the statutory on-sale bar." The court ruled that a sale of a patented invention more than a year before filing the patent is enough to invalidate the invention, even if the invention itself was not disclosed by the sale. While this ruling might indicate that all sales, whether public or not, are invalidating events, it is important to note that the court "declined the invitation by the parties to decide this case more broadly than necessary," focusing on the facts of the sales in the present case, discussed below.

Helsinn had four patents covering its anti-nausea drug Aloxi. Three of the patents were subject to pre-AIA interpretation and one was subject to post-AIA interpretation. Almost two years before applying for a patent, Helsinn entered into a licensing agreement and a supply and purchase agreement with MGI Pharma. The agreements collectively identified the product, the price, method of payment, and method of delivery, as well as an acknowledgment of FDA testing of the drug. Almost all terms of the agreement were publicly disclosed, except the price terms and the specific dosage formulations covered by the agreements. Further, the Aloxi drug had been tested successfully in clinical studies at the specific dosage formulations ultimately covered by the claims of the issued patents more than a year before any patent filing. The FDA did not approve the drug until July 2003, less than six months after Helsinn had filed its first patent application on January 30, 2003.

Helsinn brought its patent infringement suit against Teva for filing an ANDA for a generic version of Aloxi. At trial, Teva argued that all of the patents were invalid based upon the sales agreement between MGI and Helsinn entered into more than a year before the filing of Helsinn's patent applications. The district court found that the sales agreement was not an invalidating on-sale activity for two reasons. First, although the court found the two agreements did qualify as sales agreements it interpreted, the "otherwise available to the public" phrase as meaning that only public sales triggered the AIA's version of the on-sale bar. Therefore, since Helsinn's sale did not disclose details of the invention (i.e., the specific dosage formulations), it was not a public sale invalidating the one post-AIA patent. Second, the district court found the invention was not reduced to practice more than a year before the patent filings because the FDA approval had not been received. As a result, the drug was not "ready for patenting"; accordingly, the sales agreement did not invalidate the three pre-AIA patents.

The Federal Circuit disagreed. The court ruled that the amendment to the on-sale bar showed Congress meant that the public disclosure of the sale itself would make the patented product available to the public; the sale does not have to disclose all of the details of the invention publicly. The court concluded that "after the AIA, if the existence of the sale is public, the details of the invention need not be publicly disclosed in the terms of sale." Therefore, the announcement of the sale was enough to invalidate the post-AIA patent. In addition, the Federal Circuit also reversed the district court's decision on the pre-AIA patents, finding that requiring FDA approval to show the invention was "ready for patenting" was too high a standard. All that is needed to determine the invention was ready for patenting was to show the invention worked as intended. As a result, all four patents were found invalid by the appeals court.

What are the takeaways from this case? A patent is unenforceable if a sale is made known to the public more than a year before the filing of the patent application, even if it does not disclose the invention itself. However, does the secret sale of an invention more than a year before a patent application is filed invalidate the patent? Given the statements above, and the court's reluctance to address that particular issue, the question as to whether private sales are invalidating acts under the on-sale bar remains open. However, such an issue can be avoided by pursuing patent protection before any sale occurs, or at least within a year of the date of sale for those jurisdictions that don't require absolute novelty.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Lewis Roca Rothgerber Christie LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Lewis Roca Rothgerber Christie LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions